NA Proactive news snapshot: Revive Therapeutics, CytoDyn, Phunware, WeedMD, Ximen Mining ...

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF), a specialty life sciences company, announced on Friday that it was expanding its research partnership with the University of Wisconsin-Madison to evaluate novel formulations of psilocybin and a Phase 1 clinical study investigating the therapeutic application of psilocybin for an undisclosed addiction use disorder. “We are pleased to have expanded our research partnership with the University of Wisconsin-Madison in the development of novel psilocybin formulations that will serve as the platform to create unique psychedelic-based therapeutics for clinical research targeting specific medical needs, such as addiction use disorders,” Revive Therapeutics CEO Michael Frank said in a statement. CytoDyn Inc (OTCQB:CYDY) announced the launch Friday of a Phase 2 clinical trial of its flagship drug leronlimab as a treatment for the liver condition non-alcoholic steatohepatitis (NASH). The 90-patient double-blind trial is designed to investigate whether leronlimab may control the liver fibrosis - the formation of large amounts of scar tissue - associated with the disease. Previously, a preclinical study showed leronlimab’s potential in treating nonalcoholic fatty liver disease (NAFLD), considered a common precursor to NASH. There are no drugs currently approved by the US Food and Drug Administration (FDA) to treat Nash, which is expected to be the leading cause of liver transplants this year, according to research published in the journal Visceral Medicine. Phunware Inc (NASDAQ:PHUN) said Friday it has struck a new partnership agreement with SALTO Systems, one of the world’s top five manufacturers of electronic access control systems. SALTO specializes in battery-operated, radio-frequency identification (RFID) locking systems for a variety of industries worldwide, including commercial, education, multi-family residential, healthcare, government, transport, hospitality and leisure, and entertainment. Phunware said the new partnership agreement allows SALTO to sell an integrated mobile access control platform, which eliminates the need for physical access cards within an easy-to-use mobile application portfolio provided by Phunware. WeedMD Inc (CVE:WMD) (OTCQX:WDDMF) revealed it has planted over 18,000 cannabis plants outdoors next to its Strathroy, Ontario greenhouse and that it's Aylmer extraction hub is now fully operational. The plants are fully rooted, planted over 27 acres, and consist of seven strains selected from mother plants shown to excel outdoors in southwestern Ontario, the company said. WeedMD, a medical-grade cannabis producer, noted that it was one of only a handful of licensed-producers entering its second year of outdoor operations. Ximen Mining Corp (CVE:XIM) (OTCMKTS:XXMMF) updated further on progress at its past producing Kenville gold mine, where it expects to have completed a new portal to the mine in July. The firm is aiming to bring the underground mine in Nelson, British Columbia, back to life. The site reportedly produced 65,236 ounces of gold and 27,686 ounces of silver between 1889 and 1956. Key to this is refurbishing the existing portal at the 257 level of the mine, and as reported in May, Ximen is adding a new steel culvert. Codebase Ventures Inc (CSE:CODE) (OTCQB:BKLLF) investee firm, World High Life Plc (AQSE:LIFE) (OTCQB:WRHLF) has said its Love Hemp subsidiary saw strong sales growth during the month of May. Love Hemp said that May’s figures, which have not yet been publicly released, were 107% higher than January’s levels. In a statement Friday, the UK-based company said that strong sales growth reflects “continued brand appeal and ongoing product innovation” as a result of Love Hemp’s focus on building its brand while destigmatizing the use of CBD in the UK. Helix BioPharma Corp. (TSX:HBP) has said that, in accordance with the Blanket Relief, which provides up to a 45-day extension for the filing of certain periodic disclosure documents, the company expects to file its interim Disclosure Documents by July 30, 2020. It also confirmed that there have been no material developments to its business since the company last provided a business update on May 14, 2020. Helix BioPharma Corp. (TSX:HBP) has said that, in accordance with the Blanket Relief, which provides up to a 45-day extension for the filing of certain periodic disclosure documents, the company expects to file its interim Disclosure Documents by July 30, 2020. It also confirmed that there have been no material developments to its business since the company last provided a business update on May 14, 2020.